Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

Acute Lung Injury Clinical Trial

— ALI  

Official title:

A Proof of Concept Study of the Safety and Efficacy of VIB7734 for the Treatment and Prevention of Acute Lung Injury (ALI) in Patients With SARS-CoV-2 Infection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04526912
• Other study ID #: VIB7734.P1.S2
• Status: Terminated
• Phase: Phase 1
• Start date: August 28, 2020
• Est. completion date: May 19, 2021

Study information

• Verified date: December 2021
• Source: Viela Bio
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims to assess the potential benefit and evaluate the safety and tolerability of a single subcutaneous (SC) dose of VIB7734 in hospitalized patients with documented infection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) with pulmonary involvement. Subjects will be administered a single dose of VIB7734 injected under the skin, assessed for efficacy for 28 days and followed for an additional 42 days.

Description:

This is a randomized, double-blind, placebo-controlled study intended to assess the potential benefit and evaluate the safety and tolerability of a single subcutaneous (SC) dose of VIB7734 in hospitalized patients with documented infection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) with pulmonary involvement. Efficacy will be assessed during the 28 days following a single administration of VIB7734. Safety will be assessed for 10 weeks following dosing. The pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of VIB7734 in patients with confirmed SARS-CoV-2 infections will also be assessed.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: May 19, 2021
• Est. primary completion date: April 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Key Inclusion Criteria:

• Hospitalized with coronavirus disease 2019 (COVID-19) pneumonia confirmed by World Health Organization criteria.

• Oxygen saturation = 94% at room air or arterial partial pressure of oxygen/fraction of inspired oxygen < 300 mm Hg and > 200 mm Hg.

• Negative influenza test.

• Lymphocyte counts < 10^3/µL and the presence of at least one of the following markers of hyperinflammation within 1 day prior to VIB7734 administration:

• Elevated high sensitivity C-reactive protein (hsCRP) > 50 mg/L

• Ferritin > 500 ng/mL

• Lactate dehydrogenase (LDH) > 300 U/L

• D-dimers > 500 ng/mL

NOTE: Other protocol defined inclusion criteria apply

Key Exclusion Criteria:

• Respiratory failure requiring mechanical ventilation.

• In the opinion of the Investigator, progression to mechanical ventilation or death is imminent and inevitable within the next 24 hours.

• Valid Do Not Intubate (DNI) or Do Not Resuscitate (DNR) order.

• Anticipated duration of hospital stay < 72 hours.

• History of allergy or hypersensitivity reaction to any component of the IP.

• Participation in another clinical study with an IP within 4 weeks prior to Day 1 or within 5 half-lives of the IP, whichever is longer. (Participation in COVID-19 antiviral or antimalarial trials may be permitted after discussion with the Medical Monitor).

• Liver cirrhosis or liver failure.

• Known human immunodeficiency virus infection.

• Known hepatitis B or known hepatitis C infection in the absence of a history of curative therapy.

• Known or suspect active or latent tuberculosis infection.

• Active bacterial, fungal, viral, or other infection (besides COVID-19).

• Clinically significant cardiac disease within 6 months.

• History of severely impaired respiratory function at baseline (not related to COVID-19) based on requirement for home oxygen of > 4 L/min or based on other medical history known to the Investigator.

• History of cancer within 12 months of enrollment.

• Receipt of chemotherapy, biologic immunomodulators (including JAK inhibitors), or immunosuppressive therapies within 8 weeks of enrollment, or receipt of rituximab or other B cell-depleting mAb therapy within 6 months.

NOTE: Other protocol defined exclusion criteria apply

Related Conditions & MeSH terms

• Acute Lung Injury
• Lung Injury
• Wounds and Injuries

Intervention

Drug:
• VIB7734
Single subcutaneous dose
• Placebo
Intravenous single dose matched to VIB7734.

Locations

Country	Name	City	State
United States	Research Site	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Viela Bio

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of patients who achieve treatment success through Day 28, defined as avoidance of death and critical illness	Critical illness is defined by respiratory failure (requiring any of the following: endotracheal intubation, oxygen delivered by high flow nasal cannula, non-invasive positive pressure ventilation, extracorporeal membrane oxygenation or clinical diagnosis of respiratory failure) or shock (systolic blood pressure < 90 mm Hg, or diastolic blood pressure < 60 mm Hg, or requiring vasopressors)	Day 1 (Baseline) through Day 28
Secondary	Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent fatal and life-threatening SAEs, Treatment-emergent Serious Adverse Events	Defined as measure of safety	Day 1 (Baseline) through Day 70
Secondary	Change in safety laboratory parameters	Safety evaluation via review of labs (white blood cell (WBC) with differential counts, hemoglobin, platelet count, liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], and total bilirubin levels), serum chemistry, cardiac troponin coagulation markers (prothrombin time [PT], partial thromboplastin time [PTT], D dimer, fibrinogen), and urinalysis)	Day 1 (Baseline) through Day 70